{
    "nctId": "NCT00110045",
    "briefTitle": "Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant",
    "officialTitle": "A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 171,
    "primaryOutcomeMeasure": "Response rate as assessed by standard criteria after completion of study treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of proven or probable invasive aspergillosis (IA)\n\n  * Patients with a diagnosis of possible IA are eligible provided they are upgraded to probable or proven IA by culture and/or histology results and Aspergillus galactomannan evaluation within 7 days after study entry\n* Meets any of the following criteria:\n\n  * Diagnosis of a hematologic malignancy\n  * Underwent autologous or allogeneic hematopoietic stem cell transplantation\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nPerformance status\n\n* Karnofsky 20-100%\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* AST and ALT \u2264 5 times upper limit of normal (ULN)\n* Bilirubin \u2264 5 times ULN\n* Alkaline phosphatase \u2264 5 times ULN\n* No severe hepatic insufficiency\n\n  * Child-Pugh score \u2264 9\n\nRenal\n\n* No severe renal failure requiring hemodialysis or peritoneal dialysis\n* Creatinine \\< 3.4 mg/dL\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective double-method contraception\n* No known HIV positivity\n* No history of allergy or adverse reaction to echinocandin drugs\n* No known bacterial infection that is not adequately treated\n* No psychological, familial, social, or geographical condition that would preclude study participation or compliance\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Disease Characteristics\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* Prior empirical antifungal therapy allowed provided treatment duration was \u2264 72 hours\n* Prior prophylactic oral antifungals allowed\n* Prior prophylactic IV fluconazole allowed\n* More than 14 days since prior and no concurrent investigational agents\n* No prior participation in this study\n* No prior echinocandins\n* No other concurrent antifungal therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}